DE602004031517D1 - ERWENDUNG EINES 67 kDa GROSSEN LAMININREZEPTORS - Google Patents

ERWENDUNG EINES 67 kDa GROSSEN LAMININREZEPTORS

Info

Publication number
DE602004031517D1
DE602004031517D1 DE602004031517T DE602004031517T DE602004031517D1 DE 602004031517 D1 DE602004031517 D1 DE 602004031517D1 DE 602004031517 T DE602004031517 T DE 602004031517T DE 602004031517 T DE602004031517 T DE 602004031517T DE 602004031517 D1 DE602004031517 D1 DE 602004031517D1
Authority
DE
Germany
Prior art keywords
effect
inhibiting
drug
laminin receptor
test compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004031517T
Other languages
English (en)
Inventor
Hirofumi Tachibana
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyushu TLO Co Ltd
Original Assignee
Kyushu TLO Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyushu TLO Co Ltd filed Critical Kyushu TLO Co Ltd
Publication of DE602004031517D1 publication Critical patent/DE602004031517D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C07K14/7055—Integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
    • G01N2333/7055—Integrin beta1-subunit-containing molecules, e.g. CD29, CD49
DE602004031517T 2003-04-01 2004-04-01 ERWENDUNG EINES 67 kDa GROSSEN LAMININREZEPTORS Expired - Lifetime DE602004031517D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003097652 2003-04-01
PCT/JP2004/004772 WO2004090541A1 (ja) 2003-04-01 2004-04-01 ６７ｋＤａラミニン・レセプターを用いた薬物のスクリーニング方法及びそれにより得られる薬物

Publications (1)

Publication Number Publication Date
DE602004031517D1 true DE602004031517D1 (de) 2011-04-07

Family

ID=33156647

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004031517T Expired - Lifetime DE602004031517D1 (de) 2003-04-01 2004-04-01 ERWENDUNG EINES 67 kDa GROSSEN LAMININREZEPTORS

Country Status (10)

Country Link
US (2) US7736856B2 (de)
EP (1) EP1617218B1 (de)
JP (2) JP4572339B2 (de)
KR (1) KR20060005353A (de)
CN (1) CN1798975A (de)
AT (1) ATE499613T1 (de)
AU (1) AU2004227240A1 (de)
CA (1) CA2523186A1 (de)
DE (1) DE602004031517D1 (de)
WO (1) WO2004090541A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2734892A1 (en) * 2008-08-18 2010-02-25 Seoul National University Industry Foundation Method for controlling cancer metastasis or cancer cell migration by modulating the cellular level of lysyl trna synthetase
AU2010229659A1 (en) * 2009-03-26 2011-11-03 Quantum Immunologics, Inc. Oncofetal antigen/immature laminin receptor antibodies for diagnostic and clinical applications
JP5797051B2 (ja) * 2011-08-05 2015-10-21 花王株式会社 脂肪細胞の分化成熟抑制剤及び／又は脂肪蓄積抑制剤の探索方法
CN104820059B (zh) * 2015-04-22 2016-07-06 湖南农业大学 一种快速筛选含有EGCG3"Me茶树资源的方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4565789A (en) * 1983-04-04 1986-01-21 The United States Of America As Represented By The Department Of Health And Human Services Cell matrix receptor system and use in cancer diagnosis and management
AU3766989A (en) * 1988-05-20 1989-12-12 La Jolla Cancer Research Foundation Adhesion receptor for laminin and its use
GB9808407D0 (en) 1998-04-22 1998-06-17 Univ Belfast Medicament
JP4507027B2 (ja) * 1998-12-04 2010-07-21 明治乳業株式会社 Ｍｍｐ阻害剤
US6410052B1 (en) * 1999-03-30 2002-06-25 Purdue Research Foundation Tea catechins in sustained release formulations as cancer specific proliferation inhibitors
JP2001114687A (ja) * 1999-10-13 2001-04-24 Mitsui Norin Co Ltd 抗癌剤
JP4205334B2 (ja) * 2000-11-24 2009-01-07 株式会社 伊藤園 茶に由来する薬理組成物
JP2002200340A (ja) * 2000-12-28 2002-07-16 Sega Corp ゲーム装置，ゲーム方法，およびゲームプログラム
US20060019256A1 (en) * 2003-06-09 2006-01-26 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer

Also Published As

Publication number Publication date
CN1798975A (zh) 2006-07-05
US20070021321A1 (en) 2007-01-25
EP1617218B1 (de) 2011-02-23
EP1617218A4 (de) 2007-04-25
US20100222424A1 (en) 2010-09-02
AU2004227240A1 (en) 2004-10-21
CA2523186A1 (en) 2004-10-21
JP2010248201A (ja) 2010-11-04
US7736856B2 (en) 2010-06-15
JP4572339B2 (ja) 2010-11-04
KR20060005353A (ko) 2006-01-17
JPWO2004090541A1 (ja) 2006-07-06
WO2004090541A1 (ja) 2004-10-21
ATE499613T1 (de) 2011-03-15
EP1617218A1 (de) 2006-01-18

Similar Documents

Publication Publication Date Title
DE602006019404D1 (de) Docetaxel-immuntest
DE602006015929D1 (de) Doxorubicin-immuntest
DE60221046D1 (de) Nachweis von sondenmolekülen, die auf einen aktiven bereich eines sensors gebunden sind
DE60315415D1 (de) Biosensor, magnetisches molekül messverfahren und messobjekt messverfahren
WO2008069881A3 (en) Gene expression profiling for identification, monitoring and treatment of melanoma
ATE525649T1 (de) Nachweis von proteinen mit veränderter konformation
NO20075671L (no) Neurodegenerative markorer for psykiatriske tilstander
ATE528649T1 (de) Verfahren zum nachweis falsch gefalteter proteine und prionen
DE602005022315D1 (en) Taxol-immunoassay
DE602005014386D1 (de) Verwendung von cyfra 21-1 und osteopontin als marker für kolorektalkarzinome
CY1112090T1 (el) Μεθοδος για ανιχνευση βιολογικων οργανισμων με χρηση σκεδασης raman
DK2038430T3 (da) Toll-Like-Receptor-4-dysfunktion og de biologiske anvendelser deraf
WO2008082529A3 (en) Gene expression profiling for identification, monitoring, and treatment of ocular disease
WO2008108873A3 (en) Molecular biosensors for detecting macromolecules and other analytes
DE602004031517D1 (de) ERWENDUNG EINES 67 kDa GROSSEN LAMININREZEPTORS
DK1664793T3 (da) Neurotoksisk aminosyre eller neurotoksisk derivat deraf forbundet med neurologiske lidelser
DE602004023824D1 (de) Verfahren zum direkten nachweis einzelner methotrexatmetabolite
DE602004027085D1 (de) M für leberkrebs sowie heilmittel gegen krebs
FR2917169B1 (fr) Procede de determination du caractere sensible ou insensible d'un hexogene.
DE50214120D1 (de) Verfahren und vorrichtung zur getreideanalyse
DK1664747T3 (da) Fremgangsmåde og indretning til påvisning af meget små partikelmængder
DE602004017317D1 (de) Verwendung der proteine proteinase 3 (prn3) und leukozyten elastatse inhibitor (ileu) als marker für kolorektale karzinome
WO2005031301A3 (en) Raman signature probes and their use in the detection and imaging of molecular processes and structures
FI20050891A0 (fi) Punnitseva sadeanturi ja sateenmittausmenetelmä
SE0702207L (sv) Förfarande vid och en anordning för opåverkad materialundersökning